Home >   Products   >  Advanced Search

2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic Acid
(CAS RN:117570-53-3 Product Number:D5235)

Structure

2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic Acid
Synonym ASA-404
Synonym DMXAA
Synonym Vadimezan

General Information

Product Number D5235

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature 0-10°C
M.F. / M.W. C17H14O4=282.30
CAS RN 117570-53-3
Related CAS RN
MDL Number MFCD00870555
Packaging and Container
  • Product Details
  • Safety & Regulations

Specification

Purity(HPLC) min. 98.0 area%

References

Reaxys-RN 4262852
RTECS# ZD5536200

GHS

Pictogram
Signal Word Warning
Hazard Statements
  • H302
  • :Harmful if swallowed.
Precautionary Statements
  • P264
  • :Wash hands and face thoroughly after handling.
  • P270
  • :Do not eat, drink or smoke when using this product.
  • P301+P312+P330
  • :IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell. Rinse mouth.
  • P501
  • :Dispose of contents/container through a waste management company authorized by the local government.

Transport Information

HS Number 2932990090

Application

DMXAA: A Compound Used as a Tumor Vascular Disputing Agent and an Immune Adjuvant

DMXAA (other names: vadimezan, ASA404) is a tumor vascular disputing agent (VDA) that can cause a specific and irreversible destruction of established tumor vessels. Reportedly, DMXAA induces apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. DMXAA showed anti-tumor effects against solid tumors in mouse models but subsequently failed in human clinical trials in 2010.
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)

References

Page Top